Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Encorafenib (LGX818)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 67,108Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer's Vision for Cancer Care at ASCO 2025 Meeting
    Pfizer's Vision for Cancer Care at ASCO 2025 Meeting

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250423613410/en/Pfizer-Advances-Bold-Vision-for-Future-of-Cancer-Care-at-the-ASCO-2025-Annual-Meeting

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    Pfizer angles Braftovi combo for full FDA approval
    Pfizer angles Braftovi combo for full FDA approval

    04 Feb 2025

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-combination-regimen-significantly

    PRESS RELEASE
    04 Feb 2025
    Share Share
    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer
    Pfizer’s BRAFTOVI Boosts Response In Mutant Colorectal Cancer

    27 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/pfizers-braftovi-combination-demonstrates-improved-response-for-mutant-metastatic-colorectal-cancer-16710

    INDPHARMAPOST
    27 Jan 2025
    Share Share
    FDA Approves Pfizer’s Braftovi for 1st-Line Treat Colorectal Cancer
    FDA Approves Pfizer’s Braftovi for 1st-Line Treat Colorectal Cancer

    20 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210321033/en

    BUSINESSWIRE
    20 Dec 2024
    Share Share
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC

    14 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913128678/en

    BUSINESSWIRE
    14 Sep 2024
    Share Share
    Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
    Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

    24 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/24/2869078/0/en/Erasca-Announces-Three-Presentations-at-the-2024-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    24 Apr 2024
    Share Share